secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001193125-25-139146
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics appoints Claire Mazumdar to board; Jami Ruben resigns
------------------------------------------------------------------------

- Jami Ruben resigned as Class III director and Audit Committee member effective June 8, 2025; no dispute or disagreement.
- Claire Mazumdar, Ph.D., appointed as Class III director and Audit Committee chair effective June 9, 2025.
- Dr. Mazumdar is founding CEO of Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage oncology company.
- She received an initial option to purchase 421,241 shares at $3.36/share, vesting monthly over three years.
- Board determined Dr. Mazumdar is independent under Nasdaq listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/0001193125-25-139146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/d948938d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-139146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer